Naurex (Evanston, IL) a clinical-stage pharmaceutical company focused on depression and other CNS-related disorders, closed a $18M Series A financing. Participants include Adams Street Partners, Latterell Venture Partners, Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire.

Akebia Therapeutics (Cincinnati, OH) a clinical-stage pharmaceutical focused on anemia and vascular disorders, closed a $22M Series B financing. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem.

Cellular Dynamics (Madison, WI) commercial-stage biotechnology company focused on the manufacturer of human induced pluripotent stem cells and tissue cells, closed a $30M Series C financing. Participants have included Tactics II Stem Cell Ventures, Equity Group Investments, Sixth Floor Investors and G Force Investments.

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

Aratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $20M Series A financing. Participants include MPM Capital, Cultivian Ventures and Avalon Ventures.

Veniti (Saint Louis, MO) a development-stage medical device company focused on iliac vein outflow obstruction, closed a $13.5M Series A financing. Participants include Baird Venture Partners and H&Q Healthcare Investors.

AssureRx Health (Mason, OH) a commercial-stage personalized medicine company focused on a pharmacogenetic platform for the determination of drug at selection and dosage, closed a $11M Series B financing. Participants include Claremont Creek Ventures, Sequoia Capital and Allos Ventures.

BridgePoint Medical (Minneapolis, MN) a clinical-stage medical device company focused on interventional cardiology for access to and treatment of chronic total occlusions, closed a $9.1M Series C financing. Participants include New Enterprise Associates, Polaris Venture Partners and Foundation Medical Partners.

NxThera (St. Paul, MN) a development-stage medical device company focused on endourology conditions, closed a $12.6M million in Series B financing. Participants include American Medical Systems, Arboretum Ventures, Aberdare Ventures and GDN Holdings.

NanoInk (Skokie, IL) a commercial-stage a protein analysis, biomaterial manufacturing and biodiscovery assay kit developer, closed a$65M Series E financing. Participants include Lurie Investment Fund.

Virtual Incision (Lincoln, NE) a development stage medical device company focused on remote operated in vivo robotic surgical laparoscopic tools and cameras, closed a $2M Series A financing. Participants include PrairieGold Venture Partners and Bluestem Capital.

And cue the confetti cannon as we celebrate the 1,000th OnBioVC.com post!

AxioMed Spine (Cleveland, OH) a clinical-stage medical device company focused on lumbar disc replacement, closed a $15M Series D financing. Participants have included Thomas, McNerney & Partners, CID Equity Partners, Early Stage Partners, Investor Growth Capital, MB Venture Partners, Primus Capital Funds and Reservoir [...]

SuperDimesnion (Minneapolis, MN) a commercial-stage medical device company focused on minimally invasive distal lung disease treatments, closed a $9.8M Series B financing. Participants include Dan Sullivan Investments, Medica Venture Partners, OrbiMed, Oxford Biosciences Partners and Pitango Venture Capital.